Injecting buprenorphine tablets: A manageable risk

Heroin Addiction and Related Clinical Problems

Volumn 8, Issue 4, 2006, Pages 29-39

  Reisinger, Marc ^a  

^a Europ Opiate Addict Treatm Assoc   (Belgium)

Author keywords

Buprenorphine misuse; Causes; Consequences; Incidence; Remedies

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; OPIATE;

AMPOULE; DRUG FORMULATION; FRANCE; GEOGRAPHIC DISTRIBUTION; HEROIN DEPENDENCE; HUMAN; INCIDENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK MANAGEMENT; TABLET;

EID: 33846357153     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. AURIACOMBE M., FATSEAS M., DUBERNET J., DAULOUEDE J. P., TIGNOL J. (2004): French field experience with buprenorphine. Am J Addict. 13 S17-S28.
2. BODKIN J. A., ZORNBERG G. L., LUKAS S. E., COLE J. O. (1995): Buprenorphine treatment of refractory depression. . J Clin Psychopharmacol 15:(1) 49-57.
3. BRUNELLE E., ROBINET S. (2004): Buprenorphine haut dosage. Evaluation d'une intervention educative sur le temps de prise sublingual. Alcoologie et Addictologie. 26:(1) 121-136.
4. BUDD K. (1981): High dose buprenorphine for postoperative analgesia. Anaesthesia. 36:(9) 900-903.
5. BUDD K. (1983): Buprenorphine. Clin Anaesthesiol. I:(1) 139-179.
6. BULLINGHAM R. E., MCQUAY H. J., DWYER D., ALLEN M. C., MOORE R. A. (1981): Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 12:(2) 117-122.
7. CASCELLA N. G., NAGOSHI C. T., MUNTANER C., WALTER D., HAERTZEN C. A., KUMOR K. M. (1994): Impulsiveness and subjective effects of intravenous cocaine administration in the laboratory. J Subst Abuse. 6:(4) 355-366.
8. COCCARO E. F. (1989): Central serotonin and impulsive aggression. Br J Psychiatry. 155 52-62.
9. COURTY P. (2003): Buprénorphine haut dosage et pratique d'injection. Ann Med Interne. 154:(Hors serie 1) 1S35-31S45.
10. EDGE W. G., COOPER G. M., MORGAN M. (1979): Analgesic effects of sublingual buprenorphine. Anaesthesia. 34:(5) 463-467.
11. EMRICH H. M., GUNTHER R., DOSE M. (1983): Current perspectives in the pharmacopsychiatry of depression and mania. Neuropharmacology. 22:(3) 385-388.
12. EMRICH H. M., VOGT P., HERZ A. (1982): Possible antidepressive effects of opioids: action of buprenorphine. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities Ann NY Acad Vol 398. The New York Academy of Sciences, New York, N.Y. pp.
13. FERONI I., PERETTI-WATEL P., PARAPONARIS A., MASUT A., RONFLE E., MABRIEZ J. C., OBADIA Y. (2005): French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis. 24:(3) 7-22.
14. FONTAA V., BRONNER C. (2001): Persistance de la pratique d'injection chez des patients substitués par méthadone ou buprénorphine haut dosage. Ann Med Interne. 152:(7S) 2S59-52S69.
15. GAGNON A., ROBINET S., BRONNER C., PARQUET P. J. (2000): Substitution des opiaces: places et role des reseaux. Analyse d'une enquete aupres des medicins generalistes. Rev Prat Medicins Generalistes. 509 1627-1635.
16. GERRA G., BORELLA F., ZAIMOVIC A., MOI G., BUSSANDRI M., BUBICI C., BERTACCA S. (2004): Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75:(1) 37-45.
17. GUICHARD A., LERT F., CALDERON C., GAIGI H., MAGUET O., SOLETTI J., BRODEUR J. M., RICHARD L., BENIGERI M., ZUNZUNEGUI M. V. (2003): Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction. 98:(11) 1585-1597.
18. HAYES M. J., FRASER A. R., HAMPTON J. R. (1979): Randomised trial comparing buprenorphine and diamorphine for chest pain in suspected myocardial infarction. Br Med J. 2:(6185) 300-302.
19. HUMENIUK R., ALI R., MCGREGOR C., DARKE S. (2003): Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction. 98:(4) 413-418.
20. JENKINSON R. A., CLARK N. C., FRY C. L., DOBBIN M. (2005): Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. 100:(2) 197-205.
21. LATKIN C. A., MANDELL W. (1993): Depression as an antecedent of frequency of intravenous drug use in an urban, nontreatment sample. Int J Addict. 28:(14) 1601-1612.
22. LAVIGNASSE P., LOWENSTEIN W., BATEL P. (2002): Economic and social effects of high-dose buprenorphine substitution therapy. Six-month results. Ann Med Interne. 153:(S3) 1S20-21S26.
23. LEJEUNE C., SIMMAT-DURAND L., GOURARIER L., AUBISSON S. (in press): Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend.
24. LEPERE B., GOURARIER L., SANCHEZ M. (2001): Diminution du nombre de surdoses mortelles a l'heroine en France depuis 1994. Ann Med Interne. 152:(S3) 5-12.
25. MAXWELL S., SHINDERMAN M. S. (1999): Optimizing Response to Methadone Maintenance Treatment: Use of Higher-Dose Methadone. J Psychoactive Drugs. 31:(2) 95-102.
26. MENDELSON J., UPTON R. A., EVERHART E. T., JACOB P., 3RD, JONES R. T. (1997): Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 37:(1) 31-37.
27. MORRISON V. (1989): Psychoactive substance use and related behaviours of 135 regular illicit drug users in Scotland. Drug Alcohol Depend. 23:(2) 95-101.
28. MUHLEISEN P., SPENCE J., NIELSEN S. (2003): Crushing buprenorphine tablets. Drug Alcohol Rev. 22:(4) 471-472.
29. NATH R. P., UPTON R. A., EVERHART E. T., CHEUNG P., SHWONEK P., JONES R. T., MENDELSON J. E. (1999): Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol. 39:(6) 619-623.
30. NESPOR K., CSEMY L. (2005): Buprenorphine abuse has become a problem in Czech Republic. Psychiatrie. 9:(4) 333-334.
31. O'CONNOR J. J., MOLONEY E., TRAVERS R., CAMPBELL A. (1988): Buprenorphine abuse among opiate addicts. Br J Addict. 83:(9) 1085-1087.
32. OBADIA Y., PERRIN V., FERONI I., VLAHOV D., MOATTI J. P. (2001): Injecting misuse of buprenorphine among French drug users. Addiction. 96 267-272.
33. REISINGER M. (1985): Buprenorphine as new treatment for heroin dependence. Drug Alcohol Depend. 16:(3) 257-262.
34. REISINGER M. (1985): Essai de traitement des heroimanes par la buprenorphine. Psychotropes. 2:(1) 76-82.
35. REISINGER M. (1988): Treatment of heroin addicts with buprenorphine: evaluation over a three-year period. NIDA Res Monogr. 81 340.
36. ROBINSON G. M., DUKES P. D., ROBINSON B. J., COOKE R. R., MAHONEY G. N. (1993): The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 33:(1) 81-86.
37. STRANG J. (1985): Abuse of buprenorphine. Lancet. 2:(8457) 725.
38. TACKE U. (2002): Abuse of buprenorphine by intravenous injection - the french connection. Addiction. 97:(10) 1355.
39. THIRION X., BARRAU K., MICALLEF J., HARAMBURU F., LOWENSTEIN W., SANMARCO J. L. (2000): Traitements de substitution de la dependance aux opiaces dans les centres de soins; le programme OPPIDUM des centres d'evaluation e d'information sur la pharmacodependance. Ann Med Interne. 151:(SA) A10-A17.
40. TOUFIK A. (1999): Distribution of intravenous injection in France. Tendance. 5.
41. UMBRICHT A., HUESTIS M. A., CONE E. J., PRESTON K. L. (2004): Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol. 24:(5) 479-487.
42. WIKLER A. (1980): A theory of opioid dependence. In: LETTIERI D. J., SAYERS M., PEARSON H. W. (Eds.): Theories on drug abuse Selected contemporary perspectives Nida Research Monograph 30. N.I.D.A., Rockville. pp. 174-178.